The binding strength between IgG and FcγR is influenced by the composition of the N-linked glycan at position N297 in the Fc-domain of IgG. Particularly, afucosylation increases the binding affinity of human IgG1 to human FcγRIIIa up to ∼20 fold, and additional galactosylation of the afucosylated IgG increases the affinity up to ∼40 fold. The increase in affinity for afucosylated IgG has previously been shown to depend on direct carbohydratecarbohydrate interactions between the IgG-Fc glycan with an N-linked glycan at position 162 unique to hFcγRIIIa and hFcγRIIIb. Here we report that the N162 glycosylation site is also found in the orthologous mouse FcγR, mFcγRIV. The N162-glycan in mFcγRIV was also responsible for enhancing the binding to mouse IgG with reduced fucose similar to hFcγRIIIa. However, unlike hFcγRIIIa, mFcγRIV did not bind more avidly to IgG with increased galactose and reduced fucose. Overall, these results suggest the N162-glycan in the human FcγRIII family and its orthologous mouse FcγRIV to be functionally conserved.
Introduction
Immunoglobulin G (IgG) is the main antibody class found in mammalian sera like humans and mice. IgG signals to the immune cells by first binding of its variable domains to foreign pathogens and then by binding of the constant domain (Fc) and subsequent crosslinking of Fcgamma receptors (FcγR) on myeloid and NK cells. The capacity of IgG to perform this task is dependent on the affinity of each IgG subclass to the different subtypes of FcγR. Furthermore, this affinity is also influenced by the composition of the conserved glycan at position Asn297 in the Fc of IgG (Dekkers et al., 2017b; Jefferis, 2009; Shields et al., 2002; Shinkawa et al., 2003; Subedi and Barb, 2015; Yasuma et al., 2016) . This bi-antennary glycan is composed of a core structure containing NAcetylglucosamine (GlcNAc) and mannose groups and can be variably extended with fucose, galactose, sialic acid and an additional bisecting GlcNAc (bisection). Particularly the absence of core fucose (referred to as afucosylation from here on) on human IgG1 increases the binding affinity to human FcγRIIIa and FcγRIIIb (collectively referred to hereafter as hFcγRIII) by up to ∼20 fold (Dekkers et al., 2017b; Shields et al., 2002) . Addition of galactose to afucosylated IgG increases the affinity even further for hFcγRIIIa by another ∼2 fold, resulting in up to ∼40x better affinity of this glycoform for FcγRIIIa (Dekkers et al., 2017b; Houde et al., 2010) . Intriguingly, galactose addition has no effect on binding of fucosylated IgG to hFcγR, and also limited effect on binding of afucosylated IgG to hFcγRIIIb (Dekkers et al., 2017b) .
Of all human FcγR, FcγRIIIa and FcγRIIIb bear a glycan at position N162 in the binding site for Fc. For those FcγR lacking the N162 glycan, the IgG Fc glycan does not seem to make strong direct contact in the interaction, and only plays a minor contribution to affinity (Sondermann et al., 2000) . However, a clear interaction has been observed between the IgG Fc-glycan and the N162-glycan of hFcγRIII (Ferrara et al., 2006) . Interestingly, artificial removal of this hFcγRIII-N162-glycan increases affinity to fucosylated human IgG (dominant glycoform found in both human and mice), suggesting this glycan in human hFcγRIIIa to sterically interfere with binding. However, the hFcγRIII-N162-glycan also discriminates between fucosylated and afucosylated human IgG (Ferrara et al., 2011) . When IgG without the Fccore-fucose residue is compared to IgG with Fc-core-fucose closer glycan-glycan interactions are observed as well as enhanced glycanprotein interactions, which explains the higher affinity (Ferrara et al., 2011) . If these interactions are also explaining the additional effects observed upon IgG-Fc galactosylation, is unknown.
For humans, the effect of the glycan composition of IgG1, in particularly fucosylation, on binding to the different FcγRs has already been thoroughly explored (Dekkers et al., 2017b; Subedi and Barb, 2016; Thomann et al., 2015) . For mice this has been less extensively studied. The mouse repertoire of FcγRs consists of four FcγRs: mFcγRI, mFcγRIIb, mFcγRIII and mFcγRIV and their function and expression pattern differs slightly from humans, as reviewed by Bruhns and Jönsson (2015) . The mouse orthologue of hFcγRIIIa is the mouse mFcγRIV . Interestingly, it has been reported that afucosylated mouse IgG2a and IgG2b have an at least 10 fold increased affinity for mFcγRIV compared to normally fucosylated mouse IgG. Unlike the human counterpart, a slight increase in binding affinity to mFcγRIIb and mFcγRIII was observed for the afucosylated antibodies . Galactosylation had no or minimal effect on binding of mouse IgG to mFcγR (Nimmerjahn et al., 2007) . However, sialylated mIgG showed an almost 10 fold decrease in affinity for mFcγRIII and mIgG2a for mFcγRIV (Kaneko et al., 2006) . The molecular mechanism by which glycosylation and sialylation of mouse IgG affect binding to mouse mFcγRIV is unknown.
Here, we investigated the effect of Asn297-glycosylation of human and mouse IgG on binding to FcγRs, with particular focus on the contribution of the N162-FcγR glycan.
Material and methods

Human and mouse IgG constructs
All restriction enzymes, ligases and accompanying buffers were from Thermo Fisher Scientific (Waltham, MA USA). Anti-human rhesus D (anti-D clone 19A10) IgG1 heavy and kappa light chain were both cloned into pEE14.4 expression vector (Lonza) as described previously (Dekkers et al., 2017a,b) . Mouse anti-KEL1 (PUMA1 clone) expression vectors for mouse IgG1 and IgG2a heavy chain and kappa light chain were cloned as described previously (Dekkers et al., 2017a; Howie et al., 2016) .
Human and mouse fusion Fc-FcγR constructs
In order to make the fusion Fc-FcγR constructs the extracellular domains of the human FcγRIIIa V158 (NCBI reference sequence: NP_001121065.1) and mouse FcγRIV (NP_653142.2) were reverse translated and codon optimized. Additionally, for both constructs a variant with N162 mutation was created. All four constructs were ordered from Geneart (Life Technologies, Paisley, UK) (FcγRIIIa variants) or Integrated DNA Technologies (Coralville, IA, USA) (FcγRIV variants) including 5′ HindIII restriction site, Kozak and 3′ EcoRI restriction site. The IgG2-Fc domain, composed of a human IgA1a hinge (PVPSTPPTPSPSTPPTPSPSCCH), human IgG2 Fc CH2 and CH3 domains including a mutation deleting the Fc-glycan (N297A), C-terminal biotinylation tag (BirATag) (GLNDIFEAQKIEW), 5′ EcoRI and 3′ EcoRV restriction sites was reverse translated, codon optimized at Geneart, and ordered from Integrated DNA Technologies (Dekkers et al., 2017b) . FcγR and IgG-Fc constructs were ligated at EcoRI restriction site and cloned into pcDNA3.1 expression vector (Invitrogen, Carlsbad, California, USA) using flanking HindIII and EcoRV restriction sites.
IgG and Fc-FcγR production and isolation
All IgGs and Fc-Fusion FcγRs were produced by transient transfection of HEK-freestyle cells (Thermo Fisher Scientific), as previously described by Vink et al. (2014) and Dekkers et al. (2016) . After 5 days the IgG-containing or Fc-Fusion-containing cell supernatant from these cells was harvested by spinning twice at maximum speed (> 4000 g) and subsequent filtration with 0.45 nm puradisc syringe filter (Whatmann, GE Healthcare, Little Chalfront, UK).
IgG and Fc-Fusion FcγR were isolated from cell supernatant with affinity chromatography columns HiTrap Protein A HP (GE Healthcare) for human IgG1, and all Fc-Fusion FcγR constructs or HiTrap Protein G HP (GE Healthcare) for mouse IgG1 and IgG2a on ÄKTA prime (GE Healthcare) according to standard procedures. Purified fractions were concentrated to concentration > 0.5 mg/mL using Protein Concentrators, 9K MWCO (Pierce, Thermo Fisher Scientific) and subsequently dialyzed against phosphate buffered saline (PBS) overnight using Slide-A-Lyzer™ Dialysis Cassettes, 10K MWCO (Thermo Fisher Scientific). Concentration of purified protein was determined using Nanodrop 2000c UV/VIS spectrophotometer (Thermo Fisher Scientific).
IgG glyco-engineering
Glyco-engineering of human IgG1 was optimized as described by Dekkers et al. (2016) . In short: To decrease either fucosylation or galactosylation 0.4 mM (for hIgG1) or 0.2 mM (for mIgG) 2-deoxy-2-fluoro-L-fucose (2FF) (Carbosynth, Berkshire, UK) or 1 mM 2-deoxy-2-fluoro-D-galactose (2FG) (Carbosynth) respectively was added to the cell suspension. To increase galactose, 1% pEE6.4 + B4GALT1 encoding β-1,4-galactosyltransferase 1 (B4GALT1) enzyme was co-transfected with 99% IgG1-κ HC + LC vector and 5 mM D-galactose (Sigma Aldrich, Saint Louis, MO, USA) was added to the cell suspension 1 h before transfection.
Mass spectrometric analysis of IgG glycan composition
IgG Fc glycan compositions of produced human IgG1 and mouse IgG1 and IgG2a were determined by mass spectrometry as described previously by Dekkers et al. (2016) and de Haan et al. (2017) . In short, trypsin-digested glycopeptide samples were analyzed by nanoLC-ESI-QTOF-MS. The separation was performed on an RSLCnano Ultimate 3000 system (Thermofisher, Breda, the Netherlands) with a gradient pump, loading pump and an autosampler. The resulting co-elution of the different glycoforms of the IgG1 Fc glycosylation site warrants fair comparison by ensuring identical ionization conditions for the various glycopeptide species. The LC was coupled to the MS detector via a CaptiveSpray source with a NanoBooster (Bruker Daltonics, Bremen, Germany). The Maxis Impact quadrupole-TOF-MS (micrOTOF-Q, Bruker Daltonics) was used as detector. MSConvert (Proteowizard 3.0) (Chambers et al., 2012) was used to convert the data files to mzXML format, and an in-house alignment tool (Plomp et al., 2015) was used to align the retention times of the data files.
A list of previously observed IgG glycans ) was used for relative quantification, after manual examination of the current data did not reveal additional glycan structures. Peptide moieties of the glycopeptides differed based on the type of IgG: hIgG1 (EE-QYNSTYR) , mIgG1 (EEQFNSTFR), and mIgG2a (EDYNSTLR) (de Haan et al., 2017) . The highest intensity of selected peaks (within an m/z window of ± 0.04 and within a time window of ± 12 s surrounding the retention time) was extracted using the inhouse developed 3D Max Xtractor software tool. If above a signal:background ratio of 3, the background-subtracted area of the first 3 isotopic peaks of each glycopeptide in both 2+ and 3+ charge state were summed, and this summed value was then divided by the total summed value of all glycopeptides per IgG subclass to arrive at a percentage for each glycopeptide. From these percentages we calculated several derived traits (fucosylation, bisection, galactosylation and sialylation) as described in ).
Fc-FcγR biotinylation
After purification, the protein was site-specifically biotinylated on the BirA tag using BirA enzyme as described by (Rodenko et al., 2006) . For biotinylation of 1 μM FcγR protein 0.00657 μM BirA ligase was used. After biotinylation overnight at 25°C the FcγR sample was bufferexchanged and subsequently concentrated in PBS pH 7.4 using Amicon Ultra centrifugal filter units (MWCO 30 kDa) (Merck, Millipore, Darmstadt, Germany).
Acquired receptors
The following FcγR were acquired from Sino Biological Inc. 
Surface plasmon resonance
Surface plasmon resonance (SPR) measurements were carried out on a IBIS MX96 (IBIS technologies, Enschede, the Netherlands) as described by (de Lau et al., 2011; Dekkers et al., 2017a) . Biotinylated human FcγRIIIa V158, mouse FcγRI, FcγRIIb and FcγRIV were purchased from SinoBiologicals (Bejing, China), biotinylated mouse FcγRIII was not available therefore His-tag conjugated mouse FcγRIII (SinoBiologicals) was used. Either human or mouse receptors along with human fusion Fc-FcγRIIIa WT and N162A or mouse fusion Fc-FcγRIV WT and N162A respectively, were simultaneously spotted using a Continuous Flow Microspotter (Wasatch Microfluidics, Salt Lake City, UT) onto a single SensEye G-streptavidin sensor (Senss, Enschede, Netherlands) allowing for binding affinity measurements of each antibody to all FcγR of one species simultaneously on the IBIS MX96 (IBIS technologies) as described by (de Lau et al., 2011) . Spotting was always in duplicate and in three-fold dilutions, ranging from 100 nM to 3 nM for mouse FcγRIIb and 30 nM to 1 nM for mouse FcγRIIb, mouse FcγRIV human fusion Fc-FcγRIIIa WT, human fusion Fc-FcγRIIIa N162A, mouse fusion Fc-FcγRIV WT and mouse fusion Fc-FcγRIV N162A in PBS 0.075% Tween-80 (Amresco, Solon, OH, USA), pH 7.4. For the Histagged mouse FcγRIII, biotinylated anti-His IgG1 (GenScript, Piscataway, NJ, USA) was spotted in duplicate and three-fold dilution onto the sensor, ranging from 1 nM to 30 nM, and 100 nM mouse FcγRIII (equally diluted in PBS 0.075% Tween-80, pH 7.4) was loaded onto the sensor before each antibody injection.
The IgGs were then injected over the chip at dilution series in PBS supplemented with 0.075% Tween-80 ranging from 0.7 nM to 1500 nM for all mouse IgG1 and IgG2a glycoforms (2-fold dilutions, 12x), and ranging from 5.8 nM to 506 nM for human IgG1 glycoforms (1.5-fold dilutions, 12x). Regeneration after each sample was carried out with acid buffer (10 mM Gly-HCL pH 2.3). The system was calibrated for slight changes in refractive index due to environmental factors by buffer composition or temperature referencing the signals on spots to signals outside spots. Calculation of the apparent dissociation constant (K D ) 'K D apparent ' was performed by fitting a 1:1 Langmuir binding model to the RU 360 values at each antibody concentration. For consistent reporting, these fits were carried out at each receptor density, and the final reported estimated K D s were calculated by interpolating to R max = 500 (Dekkers et al., 2017a; Schasfoort et al., 2016) . In the case of mouse FcγRIII, anti-His association and dissociation curves were subtracted before calculation of IgG-binding affinity using SPRINT 1.9.4.4 software (IBIS technologies). Analysis and calculation of all binding data was carried out with Scrubber software version 2 (Biologic Software, Campbell, Australia).
Statistical analysis
All statistical analyses were performed using Graphpad Prism software version 7.02 (San Diego, CA, USA). Error bars represent one standard deviation and significance was determined by a p-value < 0.05.
Results
Affinity of human IgG glycovariants to human FcγRIIIa
To probe the effect of the N162-glycan found in human FcγRIII, we first generated recombinant hFcγRIIIa variants with or without the Nlinked glycan (WT or N162A) as Fc-Fusion proteins, with the Fc part lacking binding affinity for FcγR (Fc: N297A), including a site-specific c-terminal biotin-label ( Supplementary Fig. 1 ).
As reported previously, removing the N162-glycan by the N162A mutation resulted in an approximately 4-fold increased affinity of unmodified fucosylated IgG1 to FcγRIIIa, with average K D apparent from 1.0 × 10 −7 to 2.6 × 10 −8 nM respectively (Fig. 1a) (Ferrara et al., 2011) , as analyzed by surface plasmon resonance (SPR). This modification was known to hamper the discrimination of FcγRIIIa between fucosylated and afucosylated human IgG1. However, to test whether the FcγRIII-N162 glycan also affects the discrimination between galactosylated IgG. We generated IgG variants, engineering the bi-antennary glycan at the level of fucose and galactose as described previously (Dekkers et al., 2017b , resulting in 6 different glycoforms as summarized in Supplementary Table 1 . The relative affinity for Fc-FcγRIIIa WT was 5-10-fold higher after afucosylation, with a 2-3-fold variation in binding being observed for the galactose variants. However, for FcγRIIIa N162A, affinities were virtually independent of levels of fucosylation and galactosylation ( Fig. 1b and Supplementary Fig. 2 ). This suggest the affinity-modulation by the hIgG glycan was solely dependent on the FcγRIII-glycan at position 162.
The N162-glycan site in hFcγRIII is conserved in mouse FcγRIV
We then investigated if a similar mechanism is operational in mice, and therefore analyzed all human and mouse FcγR for their presence of the N162-glycan found in both human FcγRIIIa and FcγRIIIb. This predicted glycosylation site was only found in the mouse orthologue receptor of hFcγRIIIa-mFcγRIV -but not in any other mouse FcγR (Fig. 2) .
Affinity of mouse IgG glycovariants to mouse FcγR
Next we tested if the combination of afucosylation and galactosylation also affects binding to mouse FcγR in a similar way as in humans (Dekkers et al., 2017b) and, in particular, if the conserved FcγRIV-N162 glycan was also responsible for discriminating between fucosylated and afucosylated IgG (as seen in Fig. 1 ). We therefore recreated those IgGglycovariants as mouse IgG, using the same methods as before (Dekkers et al., 2017b . This resulted in 6 mIgG1 and 6 mIgG2a variants with high or decreased fucosylation and either decreased or increased galactosylation (Supplementary Tables 2 and 3) .
For mouse IgG1 we detected only binding to mFcγRIIb and mFcγRIII. The affinity of mIgG1 to these receptors was similar as reported earlier (Dekkers et al., 2017a; (Fig. 3a) . IgG produced with low amount of fucose, with high, intermediate or low levels of galactose of mIgG1 did not strongly influence its binding to neither receptor (Fig. 3b, Supplementary Fig. 3a and b) . mIgG2a bound all mouse FcγR and affinity was also similar to what we and others reported earlier (Dekkers et al., 2017a; (Fig. 3c) . Similar variation in glycosylation of mIgG2a affected the affinity to all mFcγR (Fig. 3d, Supplementary Fig. 3c-f) , although the changes for FcγRI, FcγRIIb and FcγRIII were only minor (≤∼2x). For mFcγRI the affinity seemed slightly decreased for afucosylated IgG, while it was slightly increased for mFcγRIIb and FcγRIII, also reported previously by . On the other hand, the increased affinity was especially pronounced for binding of afucosylated mIgG2a to mFcγRIV, but unlike the binding of human IgG1 to human FcγRIIIa (Fig. 1b) , we observed no additional effect of galactosylation for binding of mIgG2a to mFcγRIV (Dekkers et al., 2017b) (Fig. 3d, Supplementary Fig. 3f ).
To investigate if the N162-glycan in mFcγRIV has similar function as in hFcγRIIIa, we generated recombinant FcγRIV variants with-or without the N-linked glycan (WT or N162A) as Fc-Fusion proteins, comparable to the hFcγRIIIa Fc-Fusion constructs ( Supplementary  Fig. 4 ). Similar to hFcγRIIIa (Fig. 1a) , an increase in binding (25x) was observed for fucosylated mIgG2a to the FcγRIV-N162A compared to WT FcγRIV ( Fig. 3e and Supplementary Fig. 3g and h) , suggesting that the FcγRIV-162-glycan also sterically interferes with recognition of fucosylated IgG.
We observed no increased binding affinity to FcγRIV-without the N162-glycan after afucosylation of mIgG2a ( Fig. 3f and Supplementary  Fig. 3g and h ). Collectively this strongly suggests the conserved N162-glycan found in the human FcγRIII family and its orthologue in mice to be the primary sensor discriminating between fucosylated and afucosylated IgG.
Discussion
The presence of the IgG-Fc glycan at position 297 is required for binding to both human and mouse FcγR in general (Shields et al., 2001; Tao and Morrison, 1989) . However, a more complex interaction takes place between human IgG and hFcγRIII (Ferrara et al., 2011) , and as we show here, also for mouse IgG and mFcγRIV. This is because these two orthologous receptors have an glycan at position N162 that for humans has been shown to interact with the IgG-Fc glycan. Here we confirmed that the glycan composition of the Fc-N297 glycan is important for the affinity of human IgG to hFcγRIIIa and that this is conserved for the affinity of mouse IgG to mFcγRIV. The main effect seen was that low fucosylation increases the affinity for these receptors, which was fully attributable to the presence of the FcγR-N162 glycan. For humans we registered an additional effect of the IgG1-Fc galactosylation on affinity for hFcγRIIIa: highly galactosylated and afucosylated IgG1 binds significantly better than low galactosylated, afucosylated IgG. However, this additional effect of galactose was not found for the mouse IgG2a -mFcγRIV interaction.
Mouse IgG glycosylation is known to be a little more complex than that of humans. The bi-antennary glycan has the same core structure as that of human IgG, but can also be extended with α1,3-galactose (α-gal) and sialic acid in the form of N-glycolylneuraminic acid (Maresch and Altmann, 2016; Mimura et al., 2016) . For this research we solely focused on engineering the residues which are known to affect human FcγRIII binding (fucose and galactose). It would be interesting to investigate the effect of the mouse specific glycan additions, but this was not possible due to the lack of available glyco-engineering tools.
By deleting the N162 FcγR-glycan sites in both human and mouse FcγRIIIa and FcγRIV, respectively, we detected increased binding to fucosylated IgG (Shibata-Koyama et al., 2009 ). Even though afucosylation of IgG did not further increase binding affinity to receptors lacking the N162-glycan, it did increase the affinity to WT FcγRIIIa or FcγRIV beyond the apparent steric impediment asserted by the N162-FcγR glycan to fucosylated IgG. This strongly suggest that the presence of this N162-glycan allows these FcγR to discriminate between fucosylated and afucosylated IgG. The N162 FcγR-glycan does not seem to be able to further discriminate for the addition of galactose in neither the human IgG1/FcγRIIIa nor the mouse IgG2a/FcγRIV interaction.
Ferrara et al. showed that the discriminatory capability of the FcγRIIIa through the N162-glycan is due to a direct carbohydrate-carbohydrate interaction, and allows for closer contact between receptor and ligand when the core-fucose is absent from the IgG N297 Fc glycan (Ferrara et al., 2011) . Although we see similar range of affinity changes with afucosylated IgG, the apparent affinities we measure are slightly different than abovementioned study. This is likely due to the differential experimental setup and/or possibly due to different states of bisection and galactosylation of IgG of which the latter is also known to affect binding to FcγRIII Houde et al., 2010; Subedi and Barb, 2016; Thomann et al., 2015) , especially when afucosylated (Dekkers et al., 2017b; Houde et al., 2010) . However, the level of IgG-galactosylation and other possible present glycan traits was not determined by Ferrara et al. (2011) . In this study, we did not analyze the composition of the FcγR-N162 glycans which may also arguably affect binding to IgG. Recently, it was shown that FcγRs produced in different cell lines vary in their glycan composition and this indeed affected binding of therapeutic antibodies (Hayes et al., 2017) . Variation of FcγRIIIa glycosylation has been found to occur in vivo on different immune cells and may thus affect IgG affinity (Edberg and Kimberly, 1997; Huizinga et al., 1990) , but the details of in vivo FcγR glycovariation are unfortunately unknown. In this study, we made use of two different FcγRIV constructs, both with a C-terminal biotin tag. These differed, with the commercial product being a monomeric construct produced in an undisclosed human cell line and our in-house FcγRIV being a hIgG2-Fc-FcγR-fusion, unable to bind FcγR through its Fc portion because it lacks the N297-linked glycan (Dekkers et al., 2017b) and separating the Fc and FcγR portions spatially through a relatively long IgA1-hinge, produced in HEK Freestyle cells. We have generated such Fc-Fusion constructs previously, without remarkable differences in affinities for IgG subclasses compared to those reported by others (Bruggeman et al., 2017; Dekkers et al., 2017a,b) . Here, however, we noticed a 3x increased affinity of afucosylated IgG2a for the Fc-FcγRIV WT construct compared to the monomeric produced FcγRIV, although the qualitative discrimination between the binding to fucosylated and afucosylated IgG was observed for both constructs. The elevated affinity of our Fc-FcγRIV might either be due to the altered configuration but also due to differences in glycan composition between the two FcγRIV constructs (Edberg and Kimberly, 1997; Zeck et al., 2011) . As hFcγRIIIa and mFcγRIV have additional glycans besides the N162-glycan it is possible that additional glycans also influence the affinity, although their effect appears minor and do not seem to affect the discrimination of afucosylated IgG1 (Shibata-Koyama et al., 2009) . The importance of the FcγR glycosylation clearly needs to be further addressed by future studies.
In summary, here we describe that the N162 found in hFcγRIIIa, which is known to provide this receptor with its discriminatory capacity for fucosylated and afucosylated IgG, is functionally conserved in mFcγRIV. Although we and others have recently described that galactosylation further increases the affinity of afucosylated human IgG to FcγRIII (Dekkers et al., 2017b; Houde et al., 2010) , this is not the case for mFcγRIV. The conserved discrimination between fucosylated and afucosylated IgG in humans and mice through a single glycan in the orthologous receptors FcγRIIIa and FcγRIV in mice and humans, respectively, is interesting in the light of recent data showing that human immune responses can be mounted with afucosylated antibodies (Ackerman et al., 2013; Kapur et al., 2015 Kapur et al., , 2014a Sonneveld et al., 2017 Sonneveld et al., , 2016 Wang et al., 2017) . This suggest a mechanism to be in place that can trigger exceptionally strong effector functions in immune responses, now described not only for allo-immune responses against red blood cells and platelets after transfusion (Kapur et al., 2015; Sonneveld et al., 2017) and in pregnancy (Kapur et al., 2014a,b; Sonneveld et al., 2016; Wuhrer et al., 2009 ), but also HIV (Ackerman et al., 2013) and Dengue (Wang et al., 2017) . Understanding of those mechanisms will allow us to tap into these to generate more potent immune responses, or prevent them when inappropriately triggered.
Conclusions
The conserved N162 glycan in human FcγRIIIa and mouse FcγRIV is responsible for the discrimination between fucosylated and afucosylated IgG Fc glycoforms. For both species afucosylated binds with much higher affinity to these homologous receptors. In humans, additional galactosylation of afucosylated IgG Fc further directs strength of affinity, this is not observed for mouse afucosylated IgG Fc.
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